Regeneron Pharmaceuticals, Inc.
REGNNASDAQHealthcare● Active
$620.97
$-14.48(-2.28%)
Market Cap$64.0B
P/E Ratio—
52W High$821.11
52W Low$476.49
Regeneron Pharmaceuticals, Inc. (REGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · REGN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Cost of Revenue | $2.10B | $1.97B | $2.24B | $1.71B | $2.72B |
| Gross Profit | $12.24B | $12.23B | $10.87B | $10.47B | $13.35B |
| Gross Margin %(computed) | 85.35% | 86.13% | 82.89% | 85.99% | 83.05% |
| Operating Expenses | |||||
| R&D Expenses | $5.85B | $5.23B | $3.99B | $3.06B | $2.62B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $8.66B | $8.24B | $6.52B | $5.08B | $4.40B |
| Operating Income | $3.58B | $3.99B | $4.35B | $5.39B | $8.95B |
| Operating Margin %(computed) | 24.95% | 28.10% | 33.15% | 44.24% | 55.67% |
| Interest Income | $0.72B | $0.71B | $0.50B | $0.16B | $0.00B |
| Interest Expense | $0.04B | $0.06B | $0.07B | $0.06B | $0.06B |
| Income Before Tax | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B |
| Income Tax Expense | $0.73B | $0.37B | $0.25B | $0.52B | $1.25B |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Net Margin %(computed) | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 |
| Wtd Avg Shares | 0.10B | 0.11B | 0.11B | 0.11B | 0.11B |
| EBITDA | $5.82B | $5.32B | $4.69B | $5.26B | $9.67B |
| EBITDA Margin %(computed) | 40.57% | 37.45% | 35.78% | 43.21% | 60.16% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Regeneron Pharmaceuticals, Inc. data
About Regeneron Pharmaceuticals, Inc. (REGN) Income Statement
Regeneron Pharmaceuticals, Inc. (REGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, REGN reported revenue of $14.34B, gross profit of $12.24B (gross margin 85.35%), and net income of $4.50B — a net profit margin of 31.41%.
Frequently asked questions
REGN · 4 questionsRegeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.34B for 2025, up 1.0% year-over-year.
REGN revenueREGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08